(Q46699062)

24 December 2017

title

Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients (English)

1 reference

24 December 2017

1 reference

Mayumi Hasegawa

1

1 reference

24 December 2017

Yasuhiko Imai

2

1 reference

24 December 2017

Masaki Hiraoka

3

1 reference

24 December 2017

Kiyomi Ito

4

1 reference

24 December 2017

Amit Roy

5

1 reference

24 December 2017

publication date

15 October 2011

1 reference

24 December 2017

Journal of Pharmacokinetics and Pharmacodynamics

published in

1 reference

24 December 2017

volume

38

1 reference

24 December 2017

issue

6

1 reference

24 December 2017

page(s)

803-832

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1007/s10928-011-9221-5

exact match

0 references

cites work

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

T cells in the pathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

T-cell regulation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Abatacept for rheumatoid arthritis: a Cochrane systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Regression modelling strategies for improved prognostic prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Model appropriateness and population pharmacokinetic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Akaike's information criterion in generalized estimating equations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Pharmacokinetic aspects of biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Population pharmacodynamic model for ketorolac analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-011-9221-5

Infliximab pharmacokinetics in inflammatory bowel disease patients.

21 January 2018

1 reference

12 December 2020

Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects

1 reference

12 December 2020

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

12 December 2020

Pathogenesis of bone erosions in rheumatoid arthritis

1 reference

12 December 2020

Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements

1 reference

12 December 2020

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

12 December 2020

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis

1 reference

12 December 2020

[Pharmacological properties and clinical efficacy of abatacept (Orencia(®)) for the treatment of rheumatoid arthritis]

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine

1 reference

12 December 2020

10.1007/S10928-011-9221-5

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017